Mizolastine is commonly used to help manage symptoms related to physical discomfort arising from conditions where functional stability becomes affected. The medicine is generally relevant for addressing conditions that present with systemic or localized discomfort.

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations, such as allergic rhinitis (seasonal and perennial) and Chronic Idiopathic Urticaria (persistent hives). It is applied across domains where additional symptomatic support is needed, helpful in situations where multiple symptoms occur together, such as sneezing, runny nose, eye and body itching, and the presence of wheals.

“It helps address symptoms that create noticeable functional strain, assisting with maintaining functional stability.”

Symptomatic Support and Comfort

The medicine is considered relevant when supportive symptom management is appropriate in situations where symptoms interfere with daily functioning. It contributes to providing supportive relief that helps ease the overall symptom burden.

Quick Fact: Support for Itching Symptoms
Symptom Focus	Intense itching (pruritus) of the skin and eyes.
Context	Chronic hives and allergic mucosal irritation.
Benefit	Helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. Mizolastine’s therapeutic use is generally associated with official product information from European regulatory files

Official Eligibility for Mastel (Mizolastine)

Eligibility for using Mastel is strictly defined by regulatory documents, focusing on age, pre-existing conditions, and concurrent medication use.

Populations Permitted and Restricted

Category	Regulatory Status
Eligible Age Group	Adults and adolescents aged 12 years and older are eligible for use.
Children Under 12	Use is not recommended as safety and efficacy are not clinically established.
Elderly Patients	Caution is advised due to potential susceptibility to effects on cardiac repolarisation.
Renal Impairment	Caution is advised in cases of moderate-to-severe renal impairment.

Absolute Contraindications (Must Not Use)

Mastel is contraindicated and must not be used in the following patient groups or circumstances:

• Patients with a known hypersensitivity to the active substance (Mizolastine) or any component of the formulation.
• Patients with significantly impaired hepatic (liver) function.
• Patients with clinically significant cardiac disease, a history of symptomatic arrhythmias, known/suspected QT prolongation, or hypokalaemia (low potassium levels).
• Concurrent use with macrolide antibiotics (e.g., systemic erythromycin) or systemic imidazole antifungals (e.g., ketoconazole) is prohibited.

Pregnancy and Lactation Status

• Pregnancy: Use should be avoided during pregnancy, particularly the first trimester, as safety has not been established.
• Lactation: Use is not recommended due to the absence of information on drug levels in maternal milk.

Mastel’s official regulatory profile is defined by restrictions on concurrent use with other products, primarily due to pharmacokinetic and pharmacodynamic interactions.

Co-administration is formally contraindicated with two main drug classes: Macrolide Antibiotics (such as Erythromycin and Clarithromycin) and Systemic Imidazole Antifungals (such as Ketoconazole and Itraconazole). This restriction is based on a pharmacokinetic interaction where these agents act as inhibitors of the Cytochrome P450 3A4 (CYP3A4) metabolic system, which significantly reduces Mizolastine’s clearance and leads to increased plasma concentrations.

Use is also contraindicated with any other medicinal product known to prolong the QT interval, including Class I and III Antiarrhythmics. This restriction stems from an additive pharmacodynamic risk that may increase the potential for serious cardiac rhythm changes.

Regulatory documents also define specific exposure alterations with other medicines. For example, co-administration results in significant increases in the Cmax and Cmin of Digoxin and the AUC and Cmin of Theophylline. Other inhibitors of hepatic oxidation, such as Cimetidine, Cyclosporin, and Nifedipine, require a use-with-caution approach due to potential increases in Mizolastine exposure.

A key population-specific restriction involves patients with significantly impaired liver function (hepatic insufficiency), in whom Mastel is contraindicated, as the reduced metabolic capacity leads to a substantial increase (50% increase in AUC) in systemic exposure. Finally, official studies document no clinically significant interaction with either food or alcohol/ethanol.

Modulation of Receptor-Mediated Signaling

Mastel acts within domains involving receptor- or enzyme-mediated signaling to modify early molecular steps that shape systemic physiological outcomes. This mechanism is applied in biological systems where specific neurotransmitters or inflammatory mediators dominate, influencing the dynamics of heightened physiological signaling.

---

Engagement with Dysregulated Process Regulators

The drug engages mechanisms that regulate overactive or dysregulated processes by initiating or suppressing signaling sequences that lead to downstream effects. This intervention is relevant in biological cascades where multiple layers of pathway activation occur, modifying downstream physiological effects.

---

Targeted Pathway Adjustment and Regulation

Mastel is relevant in systems where targeted pathway adjustment is required and supports the regulation of processes driven by distinct signaling patterns. By modifying these key pathways associated with heightened physiological responses, the drug reduces the magnitude of excessive mediator signaling.

The administration of Mastel, which contains the active substance Mizolastine, is established to ensure consistent usage patterns. The medicine is available as a single, oral form: the 10 mg film-coated tablet. It is intended for systemic administration via the oral route, with a standardized schedule that applies across the intended user population. Dosing is based on a simple, non-divisible regimen.

---

Official Dosing and Administration

Feature	Official Instruction
Dosing Schedule	10 mg once daily.
Administration Frequency	Once daily, without dividing the tablet.
Timing in Relation to Meals	May be taken with or without food, as clinically significant interactions requiring specific timing have not been identified.
Tablet Handling	The tablet must be swallowed whole and should not be crushed or chewed, a constraint related to its formulation.

---

Population Use Constraints

The standard 10 mg once daily dose is designated for use by adults, including the elderly, and adolescents 12 years of age and over. Use is not recommended for children under the age of 12. Furthermore, the protocol supports sustained, long-term administration for ongoing management, as efficacy has been observed to be maintained over time. These explicit instructions define the full administration protocol.

Research evidence / Overview of studies for Mastel

Research has explored Mastel in studies involving conditions characterized by fluctuating or episodic manifestations. Studies have been conducted in settings exploring how symptoms change over time, including observational settings evaluating daily-life functioning and trials relevant in trials assessing short-term or episodic symptom patterns. These efforts were applied in studies examining patient-reported experiences, focusing on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. The research examined various scenarios, including studies conducted during periods of increased symptom activity and those focusing on episodes where symptoms become more noticeable.

In these studies, the findings describe patterns observed in the studies related to changes measured during the study period. For the populations evaluated in these trials, studies monitored outcomes related to systemic or functional imbalance. Studies observed patterns where outcomes related to systemic or functional imbalance were evaluated, and data describe patterns related to outcomes describing episodic or acute changes. Research highlights changes measured during the study period and studies report how symptoms evolved in the observed populations. However, these findings describe group patterns, not personal outcomes, and the research provides context but not individual predictions.

It is important to understand that the evidence is limited for some aspects, and long-term effects are not fully established. For specific areas of research, findings were mixed, and the data are still emerging, meaning certainty remains low in those areas. Research is ongoing to provide more clarity. The results apply only to the populations studied, and the follow-up durations were limited in many studies. Furthermore, comparative evidence is lacking for some key questions, and evidence quality varies across studies. This information highlights what is known — and what is still uncertain. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly or experience the same outcome.

Common questions about Mastel (FAQ)

Q: How is Mastel different from older medications used for a similar purpose?

Official documents classify Mastel as a second-generation H1-antihistamine. The second-generation classification is associated with being more selective for peripheral receptors, which may result in a reduced potential for central nervous system effects, such as sedation. This information is based on the general pharmacological description of the drug class.

---

Q: Is it typical to experience certain side effects when first starting a course of Mastel? / Do the common side effects of Mastel usually lessen or disappear over time?

According to the official safety profile, certain common effects like drowsiness (somnolence) and fatigue (asthenia) are noted as being transient. This classification suggests that such effects are often more apparent during the initial period of treatment. Official documents describe this pattern to provide context regarding the observed duration of these effects in studies.

---

Q: What is the typical timeframe for an initial effect from Mastel?

Studies and official information indicate that Mastel is absorbed rapidly after being taken by mouth, typically reaching peak plasma concentrations within approximately one hour. Pharmacodynamic data suggests that the drug's intended action may begin to be observed between 40 and 60 minutes following administration, based on observations in clinical research.

---

Q: What is the half-life of Mastel as reported in official pharmacokinetic data?

The half-life refers to the time it takes for half of the drug to be processed or eliminated from the body. Official pharmacokinetic documents report that the terminal elimination half-life of Mizolastine (the active substance) is generally within the range of 7 to 17 hours. One study reported a mean half-life of approximately 13 hours.

---

Q: What is the maximum duration of treatment with Mastel that has been studied?

Clinical studies assessing long-term safety and efficacy have examined the use of Mastel for extended periods. Research involving patients with long-standing conditions has reported findings sustained over a period of up to 12 months. This timeframe represents the maximum duration evaluated in certain pivotal clinical trials.

Mastel (Mizolastine) tablets require specific storage conditions to maintain their stability, as defined by official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 25 C in a cool and dry place.
Protection	The tablets must be protected from light.
Child Safety	Keep the medicine out of the sight and reach of children.

The product should be kept in its original packaging. Storage is only valid up to the expiration date, provided the tablets do not show signs of discolouration or deterioration.

Disposal Instructions

Unused or expired Mizolastine must be disposed of in accordance with local/regional pharmaceutical waste regulations. The medicine must not be discarded into drains, water courses, or household waste to prevent environmental contamination.